Our mission
First-in-class Targets, Best-in-class Vaccines
iPSC-based vaccination represents a novel approach to cancer treatment
with the ability to engage a multi-faceted anti-tumor response
Board of Directors
-
Lynne A. Bui, MD
Co-Founder, President, CEO, and Chairman of the Board
-
Joseph C. Wu, MD, PhD
Co-Founder and Board Member
-
Jürgen Eckhardt, MD, MBA
Board Member
-
Lucio Iannone, PhD
Board Member
Scientific Advisors
-
Lisa Butterfield, PhD
Vice President of Research & Development Parker Institute
-
Ian Frazer, MD, PhD
CEO & Director of Research/Professor Translational Research Institute/University of Queensland
-
John Zalcberg, MD, PhD
Head of Cancer Research Monash University
-
Ronald Levy, MD
Robert K. and Helen K. Summy Professor Stanford School of Medicine
For Investors
Learn more about what we do and how you can get involved.
Learn more